Lek Pharmaceuticals D.d.

Zoran Ham

Anton Copar

Ljubomir Antoncic

Andrej Premrl

Lidija Vranicar Savanovic

Borut Furlan

Breda Husu-Kovacevic

Martin Crnugelj

Janez Rzen

Peter Svete

Boris Marolt

Breda Husu-Kovacecic

The present invention relates to a cabergoline crystal form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and to pharmaceutical compositions containing the new form.

Crystal form of cabergoline

The present invention belongs to the field of pharmaceutical industry and relates to novel crystalline omeprazole sodium ethanol solvate and to the process for its preparation, which acts as intermediary compound to the processes for its conversion into different crystalline forms, first of all to a known omeprazole sodium form A, with low amount of residual solvents, i.e. less than 0.5% by weight of residual solvent. The present invention also relates to novel crystalline omeprazole sodium form E and crystalline omeprazole sodium form F as well to the processes for their preparation as well, both with considerably low levels of residual solvents. Omeprazole sodium form A and both novel crystalline forms omeprazole sodium form E and form F are useful for the treatment of gastrointestinal disorders.

Crystalline solvate of omeprazole sodium

Pharmaceutically suitable crystalline and amorphous alkali and earth-alkali salts of 2-n-butyl-4-chloro-5-hidrox-ymethyl-1-[[2'-(1 H-tetrazole-5-yl)[1.1&#x2032;-biphenyl]-4-yl]-1 Himidazole have been prepared and new manufacturing, purification and isolation procedure for said salts in high purity have been described. Stable pharmaceutical compositions containing new crystalline potassium salts of 2-n-butyl-5-chloro-5hidroxymethyl-1-[[2&#x2032;-(1H-tetrazole-5-yl)[1.1&#x2032;-biphenyl]-44-yl]-1H-imidazole have been prepared.

Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods

Growing community of inventors

Trbovlje, Slovenia

Zoran Ham